ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence

This study is currently recruiting participants.
Verified by Assistance Publique Hopitaux De Marseille, May 2008

Sponsored by: Assistance Publique Hopitaux De Marseille
Information provided by: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT00682552
  Purpose

Relationship between HPV infection and cervical cancer is well established. Among the HPV types identified to date, 15 are classified as high risk HPV (HR-HPV). Detection of HR-HPV has been proposed to optimize cervical cancer screening.


Condition Intervention
Cervical Intraepithelial Neoplasia
Procedure: A cervico-vaginal cervical smear

MedlinePlus related topics:   Cancer   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Diagnostic, Open Label, Single Group Assignment
Official Title:   Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence

Further study details as provided by Assistance Publique Hopitaux De Marseille:

Primary Outcome Measures:
  • The detection and the quantification of the DNA of the human oncogènes papillomavirus of type 16 and 18 [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The detection of the markers of the integration of the genome of the human oncogenes papillomavirus (targeted at the gene E2) [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:   600
Study Start Date:   May 2008
Estimated Study Completion Date:   December 2012
Estimated Primary Completion Date:   March 2012 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental

A cervico-vaginal cervical smear will be realized before every colposcopique examination.

A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized.

Procedure: A cervico-vaginal cervical smear
12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.

Detailed Description:

A prospective detection and quantification of HR-HPV in patients with proven CIN1 will be performed. Relationship between HR-HPV initial viral load and the CIN1 persistence will be evaluated.

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • The women whose last one FCV of screening put in evidence a LIEBG of the neck of the womb having been confirmed by the colposcopie.
  • The inclusive patients will be of more than 18 years old. All the patients will be profitable of a regime of Social Security.

Exclusion Criteria:

  • The patients whose result of the colposcopie is clashing with that of the FCV of initial screening (normal collar, LIEHG or the other one).
  • The patients having an antecedent of DREGS of the neck of the womb, that this one was or not handled
  • The patients having had a hysterectomy.
  • The patients incapable to receive the information enlightened on the progress and the objectives of the study
  • The patients not having signed enlightened assent
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00682552

Contacts
Contact: Xavier CARCOPINO, MD     49-196-4672     xcarco@free.fr    
Contact: Léon BOUBLI, MD     49-196-4672     leon.boubli@ap-hm.fr    

Locations
France
Hopital Nord- Service de gynécologie-obstétrique     Recruiting
      MARSEILLE, France, 13015
      Contact: Xavier CARCOPINO, MD     49-196-4672     xcarco@free.fr    

Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille

Investigators
Principal Investigator:     Xavier CARCOPINO, MD     Assistance Publique des Hopitaux de Marseille    
  More Information

Responsible Party:   Assistance Publique des Hopitaux de Marseille ( Assistance Publique des Hopitaux de Marseille )
Study ID Numbers:   2007-A01336-48, 2007-31
First Received:   May 19, 2008
Last Updated:   May 22, 2008
ClinicalTrials.gov Identifier:   NCT00682552
Health Authority:   France: Ministry of Health

Study placed in the following topic categories:
Cervical intraepithelial neoplasia
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Carcinoma
Cervical Intraepithelial Neoplasia

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers